Hologic Acessa ProVu, Руководство пользователя

Страница: 27 / 42

Acessa ® ProVu System User’s Guide PL-01-0040
CO 20-131 Revision: C 26
Percent Change From Baseline in Total Uterine and Fibroid Volume at 3 and 12 Months Post treatment Based on
Preoperative and Postoperative MRI Assessments
13.11. UFS-QOL Scores
Mean Health-Related Quality of Life (HRQL) scores and Symptom Severity Scores (SSS) improved significantly from
baseline to 3 months, then remained similar at all intervals between 3 and 36 months post treatment.
UFS-QOL Symptom Severity and HRQL Scores at Baseline and at 3, 6, 12, 24, and 36 Months Post Treatment
UFS-QOL Concern, Activities, Energy/Mood, Control, Self-Consciousness, and Sexual Function Scores at 3, 6, 12, 24, and
36 Months Post Treatment
-16%
-25%
-38%
-44%
-60%
-50%
-40%
-30%
-20%
-10%
0%
Month 3 Month 12
%
C
ha
ng
e
Fr
om
B
as
el
in
e
Uterine Volume
Fibroid Volume
61
29
29
27
25
29
37
75
78
80 79
76
0
10
20
30
40
50
60
70
80
90
Baseline
(n=127)
Month 3
(n=124)
Month 6
(n=125)
Month 12
(n=124)
Month 24
(n=112)
Month 36
(n=107)
M
ea
n
Tr
an
sf
or
m
ed
U
FS
-QO
L S
co
re
s
Symptom
Severity
HRQL
25
37
38
45
38
45
67
77
75
81
75 75
69
79
79
84
77
75
71
80
80
86
80
79
71
81
79
86
82
74
68
77
76
83
78
74
0
10
20
30
40
50
60
70
80
90
100
Concern Activities Energy Control Self-Conscious Sexual Function
M
ea
n
Tr
an
sf
or
m
ed
U
FS
-QO
L S
co
re
s
Baseline
(n=127)
Month 3
(n=124)
Month 6
(n=125)
Month 12
(n=124)
Month 24
(n=112)
Month 36
(n=107)